6
Oct 1 (Reuters) – Eli Lilly and Company: * LILLY'S ORAL GLP-1, FOUNDAYO (ORFORGLIPRON), DEMONSTRATED CARDIOVASCULAR SAFETY ALONGSIDE SUSTAINED A1C REDUCTION AND WEIGHT LOSS IN ITS LARGEST AND LONGEST
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
